App-Quantinova.ai

T CELL LINEAGE MIXED CHIMERISM IN ACUTE LEUKAEMIA/MDS- IS IT PROGNOSTIC - A SINGLE CENTRE RETROSPECTIVE STUDY

Vipul Sheth - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Alpha-thalassemia myelodysplasia syndrome

Alemtuzumab

LONG-TERM FOLLOW-UP OF RECOVERED MPN PATIENTS WITH COVID-19

Tiziano Barbui - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Myeloid neoplasms

N/A

THE PATIENT EXPERIENCE OF ACUTE LYMPHOBLASTIC LEUKEMIA AND ITS TREATMENT: A SOCIAL MEDIA REVIEW

Ross Morrison - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

MODIFIED DELPHI CONSENSUS ON THE RELEVANCE OF MINIMAL RESIDUAL TESTING IN MULTIPLE MYELOMA IN THE CLINICAL PRACTICE

Karthik Ramasamy - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

FUNCTIONAL COOPERATION OF CEBPA AND TET2 MUTATIONS IN ACUTE MYELOID LEUKEMIA

Elizabeth Heyes - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

CMML PATIENTS UNDERGOING ALLOGENEIC HCT HAVE INFERIOR SURVIVAL OUTCOMES IN COMPARISON WITH MDS PATIENTS DUE TO A SIGNIFICANTLY HIGHER RELAPSE RATE. A REGISTRY STUDY OF THE EBMT-CMWP

Alicia Rov - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic myelomonocytic leukemia

Allopurinol

RETROVIRAL GENE THERAPY FOR THE TREATMENT OF ADA-SCID: LONG-TERM FOLLOW UP AND FIRST CASE OF T-CELL ACUTE LEUKAEMIA DUE TO INSERTIONAL MUTAGENESIS

Maria Pia Cicalese - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute Leukemia

Busulfan

BETIBEGLOGENE AUTOTEMCEL GENE THERAPY FOR THE TREATMENT OF TRANSFUSION-DEPENDENT Β-THALASSEMIA: UPDATED LONG-TERM EFFICACY AND SAFETY RESULTS

Evangelia Yannaki - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Thalassemia

Busulfan

RETROSPECTIVE ASSESSMENT OF TREATMENT PATTERNS AND RESOURCE UTILIZATION FOR PATIENTS NEWLY DIAGNOSED WITH ACUTE MYELOID LEUKEMIA IN CANADA, UK, FRANCE, GERMANY, ITALY, AND SPAIN

Manasee V. Shah - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

L-Tyrosine

A PHASE 2 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE VERSUS IDELALISIB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (LOTIS-6)

Carmelo Carlo-Stella - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Follicular lymphoma

Idelalisib

COASTAL: A PHASE 3 STUDY OF THE PI3KΔ INHIBITOR ZANDELISIB WITH RITUXIMAB (R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN’S LYMPHOMA (INHL)

Wojciech Jurczak - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non-Hodgkin's Lymphoma

Lenalidomide

THE EFFECT OF MYELOMA INDUCTION THERAPY TYPE AND DURATION ON PERIPHERAL BLOOD STEM CELL HARVEST FOR AUTOLOGOUS STEM CELL TRANSPLANTATION

Charlotte Pawlyn - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Cyclophosphamide

EFFECTIVENESS OF ROMIPLOSTIM ON PLATELET ENDPOINTS AMONG PATIENTS WITH NEWLY DIAGNOSED, PERSISTENT AND CHRONIC IMMUNE THROMBOCYTOPENIA IN ROUTINE CLINICAL PRACTICE IN DENMARK, SWEDEN, AND NORWAY

Christian Fynbo Christiansen - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

Romiplostim

DEMOGRAPHIC, CLINICAL CHARACTERISTICS AND MORTALITY OF ADULT HEMATOLOGICAL CANCER PATIENTS WITH VENO-OCCLUSIVE DISEASE IN ENGLAND, 2010 TO 2020

Indraraj Umesh Doobaree - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Graft-versus-host disease

Hydroxyzine

THE CONSEQUENCES OF UNNECESSARY REQUESTING AND REPORTING OF THE DIRECT ANTIGLOBLIN TEST IN NEONATES.

Samantha Bonney - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

FA-8

PH3 STUDY OF EFFICACY AND SAFETY OF IPTACOPAN (LNP023), AN ORAL COMPLEMENT FACTOR B INHIBITOR, IN PTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND RESIDUAL ANEMIA DESPITE ANTI-C5 ANTIBODY TREATMENT

Antonio M. Risitano - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Paroxysmal nocturnal hemoglobinuria

Eculizumab

EFFICACY AND SAFETY OF MOGAMULIZUMAB BY PATIENT BLOOD CLASSIFICATION

Julia Scarisbrick - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Mogamulizumab

IMPACT OF SICKLE CELL DISEASE ON DAILY LIFE IN PATIENTS MANAGING VASO-OCCLUSIVE CRISES AT HOME VS THE EMERGENCY ROOM/HOSPITAL: RESULTS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)

Erfan Nur - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

TWO CURRENTLY RECRUITING PHASE III TRIALS: COMMODORE 1 AND 2 EVALUATING CROVALIMAB VS ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WITH OR WITHOUT CURRENT ANTI–COMPLEMENT THERAPY

Austin Kulasekararaj - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Paroxysmal nocturnal hemoglobinuria

Eculizumab

BONE MINERAL DENSITY IS STABLE IN ADULTS WITH PYRUVATE KINASE DEFICIENCY RECEIVING LONG-TERM TREATMENT WITH MITAPIVAT

Hanny Al-Samkari - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Pyruvate kinase (PK) deficiency

AG348

Filters

45280 Abstracts